Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Sacituzumab govitecan-hziy
Synonyms
Therapy Description

Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate (ADC) composed of a monoclonal anti-TROP2 antibody linked to the active metabolite of irinotecan (SN-38), which binds to TROP2 positive cancer cells and induces DNA breakage and apoptosis (PMID: 26541586). Trodelvy (sacituzumab govitecan-hziy) is FDA approved for use in patients with metastatic triple-negative breast cancer who received two or more prior therapies, in patients with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies, and in patients with locally advanced or metastatic urothelial cancer who received a platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Sacituzumab govitecan-hziy Trodelvy IMMU-132|Sactizumab|Sacituzumab govitecan TROP2 Antibody 13 Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate (ADC) composed of a monoclonal anti-TROP2 antibody linked to the active metabolite of irinotecan (SN-38), which binds to TROP2 positive cancer cells and induces DNA breakage and apoptosis (PMID: 26541586). Trodelvy (sacituzumab govitecan-hziy) is FDA approved for use in patients with metastatic triple-negative breast cancer who received two or more prior therapies, in patients with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies, and in patients with locally advanced or metastatic urothelial cancer who received a platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06235216 Phase II Sacituzumab govitecan-hziy Sacituzumab govitEcan in THYroid Cancers (SETHY) Recruiting ESP 0
NCT04579224 Phase III Sacituzumab govitecan-hziy Eribulin Gemcitabine Eribulin + Gemcitabine Docetaxel Paclitaxel Comparing the New Anti-cancer Drug Eribulin With or Without Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer Recruiting USA 0
NCT05382299 Phase III Nab-paclitaxel Carboplatin + Gemcitabine Sacituzumab govitecan-hziy Paclitaxel Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer (ASCENT-03) Recruiting USA | TUR | SVK | ROU | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG 11
NCT04647916 Phase II Sacituzumab govitecan-hziy Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases Recruiting USA 0
NCT02574455 Phase III Sacituzumab govitecan-hziy Capecitabine + Eribulin + Gemcitabine + Vinorelbine ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer (ASCENT) Completed USA | GBR | FRA | ESP | DEU | CAN | BEL 0
NCT03547973 Phase II Sacituzumab govitecan-hziy Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer Recruiting USA | TUR | ITA | GRC | GBR | FRA | ESP | DEU 1
NCT06243393 Phase II Sacituzumab govitecan-hziy Sacituzumab Govitecan in Metastatic Colorectal Cancer (TROPHIT1) Recruiting DEU 0
NCT04251416 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma Recruiting USA 0
NCT04595565 Phase III Sacituzumab govitecan-hziy Cisplatin Carboplatin Capecitabine Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (SASCIA) Active, not recruiting IRL | FRA | ESP | DEU | CHE | BEL | AUT 0
NCT03725761 Phase II Sacituzumab govitecan-hziy IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy Active, not recruiting USA 0
NCT06161532 Phase II Atezolizumab + Sacituzumab govitecan-hziy Sacituzumab govitecan-hziy Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer Recruiting USA 0
NCT03995706 Phase I Sacituzumab govitecan-hziy Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0 Completed USA 0
NCT05581589 Phase II Sacituzumab govitecan-hziy Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer Recruiting USA 0
NCT05633667 Phase II Etrumadenant + Sacituzumab govitecan-hziy + Zimberelimab Carboplatin + Paclitaxel + Zimberelimab Carboplatin + Nab-paclitaxel + Zimberelimab Docetaxel Etrumadenant + Zimberelimab Cisplatin + Pemetrexed Disodium + Zimberelimab Carboplatin + Pemetrexed Disodium + Zimberelimab AB154 + Sacituzumab govitecan-hziy + Zimberelimab AB154 + Etrumadenant + Zimberelimab Sacituzumab govitecan-hziy Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Recruiting USA | ISR | GBR | BRA 3
NCT05552001 Phase III Sacituzumab govitecan-hziy Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer (ISIdE) Recruiting FRA 0
NCT06312176 Phase III Paclitaxel Capecitabine Pegylated liposomal doxorubicin Nab-paclitaxel Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) Recruiting USA | TUR | SWE | ROU | POL | NZL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | CHE | CAN | BRA | BEL | AUS | ARG 12
NCT05838521 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer Recruiting USA 0
NCT06477419 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan in People With Mesothelioma Recruiting USA 0
NCT04230109 Phase II Sacituzumab govitecan-hziy Sacituzumab Govitecan In TNBC (NeoSTAR) Recruiting USA 0
NCT05332561 Phase II Olaparib Ipatasertib Sacituzumab govitecan-hziy Inavolisib Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) Recruiting DEU 0
NCT05833867 Phase I Sacituzumab govitecan-hziy Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer Recruiting USA 0
NCT04559230 Phase II Sacituzumab govitecan-hziy Sacituzumab Govitecan in Recurrent Glioblastoma Recruiting USA 0
NCT06248515 Phase II Sacituzumab govitecan-hziy A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors Recruiting USA 0
NCT06486441 Phase III Doxorubicin Paclitaxel Sacituzumab govitecan-hziy Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) (ASCENT-GYN-01) Recruiting USA 0
NCT04468061 Phase II Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC Recruiting USA 0
NCT04617522 Phase I Sacituzumab govitecan-hziy Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan-hziy in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment Recruiting USA | FRA 0
NCT05089734 Phase III Docetaxel Sacituzumab govitecan-hziy Study of Sacituzumab Govitecan-hziy (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-programmed Death Protein 1 (PD-1)/Programmed Death Ligand 1 (PD-L1) Immunotherapy (EVOKE-01) Active, not recruiting USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | AUS 4
NCT05884320 Phase II Sacituzumab govitecan-hziy Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Salivary Gland Cancers Recruiting USA 0
NCT06178588 Phase II Sacituzumab govitecan-hziy Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma Recruiting USA 0
NCT06409390 Phase I Fulvestrant + Ribociclib Trastuzumab deruxtecan Sacituzumab govitecan-hziy Capecitabine Abemaciclib + Fulvestrant Cyclophosphamide + Docetaxel + Sargramostim Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer Recruiting USA 0
NCT06028932 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients Recruiting USA 0
NCT05840211 Phase III Paclitaxel Capecitabine Nab-paclitaxel Sacituzumab govitecan-hziy Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07) Active, not recruiting USA | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG 11
NCT06081244 Phase II Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) (ADAPT-TN-III) Recruiting DEU 0
NCT05226117 Phase II Sacituzumab govitecan-hziy Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer Unknown status ITA 0
NCT04448886 Phase II Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Active, not recruiting USA 0
NCT03964727 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) Active, not recruiting USA | FRA | ESP | CAN | BEL | AUS 2
NCT06236269 Phase II Sacituzumab govitecan-hziy HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan (ACROSS-TROP2) Recruiting ESP 0
NCT06263543 Phase II Sacituzumab govitecan-hziy Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC (SERIES) Recruiting USA 0
NCT04527991 Phase III Paclitaxel Docetaxel Vinflunine Sacituzumab govitecan-hziy Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04) Active, not recruiting USA | TUR | SWE | ITA | ISR | IRL | HRV | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BGR | BEL | AUT | AUS 8
NCT03901339 Phase III Eribulin Gemcitabine Vinorelbine Capecitabine Sacituzumab govitecan-hziy Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer (TROPiCS-02) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 0
NCT06123468 Phase Ib/II Sacituzumab govitecan-hziy Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma Active, not recruiting DEU | AUT 0


Additional content available in CKB BOOST